Uncategorized

GT20029 China Phase II Trial For AGA Reached Primary Endpoint

Kintor Pharmaceutical Limited announced that the China phase II clinical trial of its in-house developed first-in-class androgen receptor proteolysis targeting chimera compound GT20029 tincture for the treatment of male androgenetic alopecia has reached the primary endpoint, with statistically significant and clinically meaningful results, as well as good safety and tolerability.

GT20029 China Phase II Trial For AGA Reached Primary Endpoint Read More »

Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results

Nicox SA, an international ophthalmology company, provided the revenue and cash position for Nicox SA and its subsidiaries for the first quarter of 2024 and financial results for Nicox SA for the full year of 2023, as approved by the Board of Directors on April 19, 2024, and provided an update on key future milestones.

Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results Read More »

Scroll to Top